Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs.

Int J Biol Macromol · 2021 · PMC7724963 · PMID 33309661

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may not be significantno p-value reported

However, it has been observed that ritonavir in combination with lopinavir does not provide any meaningful benefit in the treatment of COVID-19 and therefore the level of inhibition of the protease may not be significant [ 35 ]. 4 Discussion The studies presented here suggest that ritonavir may be a possible inhibitor of the 3′ to 5′ exoribonuclease activity of the SARS-CoV-2-nsp14 enzyme.

also in 2,774 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.